Article
Segment 8: Putting Patient Safety and Outcomes First in HCV Decisions
Although the Adverse Events report found Viekira Pak may not be as safe as Sovaldi and Harvoni, Express Scripts complimented that information with its own real-world data from 85 million patients before choosing Viekira Pak.
Although the Adverse Events report found Viekira Pak may not be as safe as Sovaldi and Harvoni, Express Scripts complimented that information with its own real-world data from 85 million patients before choosing Viekira Pak.
Express Scripts found that patients getting Sovaldi with ribavirin only had a 3% discontinuation rate due to the ribavirin. In addition, the company looked at how many hepatitis C patients were on other drugs that could result in potential drug-drug interactions. He added that they use their own research, reports from companies like Adverse Events, and data from the FDA to make formulary decision.
“This is constantly allowing us to re-look at our decisions because we’ve always got to put patient safety and outcomes first,” Dr Miller said.
